Background: Autism Spectrum Disorder (ASD) is a neurodevelopmental disorder with limited effective medical treatments targeting core symptoms. Leucovorin (folinic acid), a bioactive form of vitamin B9, has demonstrated efficacy in improving communication and behavioral outcomes in children with ASD, particularly those with cerebral folate deficiency or folate receptor alpha autoantibodies (FRAA). Critically, therapeutic benefit diminishes as children age, underscoring the value of earlier intervention.

Observation: A case study of two FRAA-positive women who supplemented with leucovorin beginning pre-conception yielded neurotypical development in both offspring through age three. A subsequent randomized pilot trial by Giorlandino et al. (2026) screened 220 women planning pregnancy and enrolled 18 FRAA-positive participants. Children born to mothers receiving leucovorin showed a markedly lower rate of ASD diagnosis at 30 months (10%) compared to those receiving standard folic acid (62.5%).

Conclusion: The accumulating evidence supports leucovorin as a safe, evidence-based prenatal intervention for mothers at elevated risk of bearing an ASD child. FRAA positivity is an actionable biomarker for identifying high-risk pregnancies. This commentary discusses the relevant biological mechanisms, reviews current clinical evidence, and offers guidance for psychiatrists who counsel or co-manage patients in perinatal or preconception contexts.